摘要
目的 :观察立普妥 (阿托伐他汀钠 )对脂蛋白的调整作用 ,探讨阿托伐他汀钠降低蛋白尿的机理。方法 :肾病综合征 (NS)患者 6 0例随机分为治疗组 30例及对照组 30例 ;对照组和治疗组分别在治疗前及治疗 8周后清晨 8时抽取静脉血 ,脂蛋白系列在BECMAN全自动生化分析仪上进行测量。强的松采用诱导缓解、移行减量及拖尾疗法 ;阿托伐他汀钠成人每次 2 0mg ,qd ,儿童 0 1mgkg- 1d- 1。结果 :肾病综合征患者组内治疗前后脂蛋白系列含量有非常显著差异 (P <0 0 1) ,治疗组和对照组治疗后组间比较脂蛋白系列含量、血浆白蛋白、 2 4h尿蛋白定量有非常显著差异 (P <0 0 1)。结论 :阿托伐他汀钠在调整NS患者脂蛋白代谢紊乱及降低蛋白尿方面有较好的疗效 ,且无明显的副作用 ,临床顺应性好 。
Objective:To observe the levels of Serum CHO、Apo A1 、Apo B100 、ALB、HDL and LDL effected by LIPITOR and further evaluate the mechanism of proteinauia decreasing by LIPITOR.Methods:60 patients with NS were randomly divided into treatment group and control group Serum CHO、Apo A1 、Apo B100 、ALB、HDL and LDL were tested by Becman Auto Biochemistry Analysis,Prednisone was adopted inducing remission、transplanting and tapering methods;LIPITOR was given to adult 20 mg/time,qd,chidren 0 1 mg kg -1 d -1 .Results:The levels of Serum CHO、Apo A1 、Apo B100 、ALB、HDL and LDL of the cases with NS before treatment were markedly higher than those after treatment ( P <0 01) After completion of therapy ,the levels of treatment group returned to normal There was significantly different between the treatment group and the control group( P <0 01) after treatment Conclusion:LIPITOR has significantly better effects on regulating CHO abnormality and decreasing proteinuria of NS There was no apparent side effect,and there was well compliance.
